Deconvoluting drug interactions using <i>M. tuberculosis</i> physiologic processes: transcriptional disaggregation of the BPaL regimen <i>in vivo</i>

A key challenge in preclinical tuberculosis drug development is identifying optimal antibiotic combinations. Drug interactions are complex because one drug may affect <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>) physiology in a way that alters the activity of another drug. Conventional pharmacodynamic evaluation based on colony-forming units (CFU) does not provide information about this physiologic interaction because CFU enumerates bacteria but does not give information about the drug's effect on bacterial cellular processes. SEARCH-TB is a novel pharmacodynamic (PD) approach that uses targeted <i>in vivo</i> transcriptional profiling to evaluate drug effects on <i>Mtb</i> physiology. To evaluate SEARCH-TB's capacity to elucidate drug interactions, we deconstructed the BPaL (bedaquiline, pretomanid, and linezolid) regimen in the BALB/c high-dose aerosol mouse infection model, measuring the effect of 2-, 7-, and 14-day treatment with drugs in monotherapy, pairwise combinations, and as a three-drug combination. Monotherapy induced drug-specific <i>Mtb</i> transcriptional responses by day 2 with continued evolution over 14 days. Bedaquiline dominated pairwise combinations with pretomanid and linezolid, whereas the pretomanid-linezolid combination induced a transcriptional profile intermediate between either drug. In the three-drug BPaL regimen, adding both pretomanid and linezolid to bedaquiline yielded a greater transcriptional response than expected, based on pairwise results. This work demonstrates that physiologic perturbations induced by a single drug may be modified in complex ways when drugs are combined. This establishes proof of concept that SEARCH-TB provides a highly granular readout of drug interactions <i>in vivo,</i> providing information distinct from CFU burden and suggesting a future where regimen selection is informed by <i>in vivo</i> molecular measures of <i>Mtb</i> physiology.

Authors

Institutions

Publication Details

Journal
Antimicrobial Agents and Chemotherapy
Published
2025-09-18
DOI
https://doi.org/10.1128/aac.00492-25
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Deconvoluting drug interactions using M. tuberculosis physiologic processes: transcriptional disaggregation of the BPaL regimen in vivo

Gregory T. Robertson, Nicholas D. Walter, Elizabeth A. Wynn, Christian Dide-Agossou et al.
Antimicrobial Agents and Chemotherapy
Tuberculosis Research and Epidemiology
article

Deconvoluting drug interactions using M. tuberculosis physiologic processes: transcriptional disaggregation of the BPaL regimen in vivo

Gregory T. Robertson, Nicholas D. Walter, Elizabeth A. Wynn, Christian Dide-Agossou, Michael A. Lyons, Andrés Obregón‐Henao, Camille M. Moore, Karen Rossmassler, Reem Al Mubarak, Martin I. Voskuil, Jo Hendrix
article en

Abstract

A key challenge in preclinical tuberculosis drug development is identifying optimal antibiotic combinations. Drug interactions are complex because one drug may affect <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>) physiology in a way that alters the activity of another drug. Conventional pharmacodynamic evaluation based on colony-forming units (CFU) does not provide information about this physiologic interaction because CFU enumerates bacteria but does not give information about the drug's effect on bacterial cellular processes. SEARCH-TB is a novel pharmacodynamic (PD) approach that uses targeted <i>in vivo</i> transcriptional profiling to evaluate drug effects on <i>Mtb</i> physiology. To evaluate SEARCH-TB's capacity to elucidate drug interactions, we deconstructed the BPaL (bedaquiline, pretomanid, and linezolid) regimen in the BALB/c high-dose aerosol mouse infection model, measuring the effect of 2-, 7-, and 14-day treatment with drugs in monotherapy, pairwise combinations, and as a three-drug combination. Monotherapy induced drug-specific <i>Mtb</i> transcriptional responses by day 2 with continued evolution over 14 days. Bedaquiline dominated pairwise combinations with pretomanid and linezolid, whereas the pretomanid-linezolid combination induced a transcriptional profile intermediate between either drug. In the three-drug BPaL regimen, adding both pretomanid and linezolid to bedaquiline yielded a greater transcriptional response than expected, based on pairwise results. This work demonstrates that physiologic perturbations induced by a single drug may be modified in complex ways when drugs are combined. This establishes proof of concept that SEARCH-TB provides a highly granular readout of drug interactions <i>in vivo,</i> providing information distinct from CFU burden and suggesting a future where regimen selection is informed by <i>in vivo</i> molecular measures of <i>Mtb</i> physiology.

Antimicrobial Agents and ChemotherapyVol. 69(11)
National Jewish Health (US), University of Colorado Anschutz Medical Campus (US), University of Colorado Denver (US), Colorado State University (US)
Openalex Percentile: Top 70%
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.